Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma

Abstract

Objective: Endocrine immune-related adverse events (endocrinopathies) are increasingly prevalent with the use of immune checkpoint inhibitors for the treatment of metastatic melanoma and other malignancies. There are no evidence-based guidelines for the screening or management of such patients. To describe the spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors. Design: A prospective study conducted at Melanoma Institute Australia between April 2014 and October 2015. Methods: A total of 177 patients were treated with (a) ipilimumab (n = 15), (b) anti-PD-1 (nivolumab, pembrolizumab) (n = 103) or (c) combination ipilimumab and anti-PD-1 (n = 59) and were screened and managed for the subsequent endocrinopathies. The main outcome measures were the incidence and kinetics of endocrinopathy by immunotherapy drug class. Results: Thirty-one patients (18%) developed an endocrine immune-related adverse event (thyroid dysfunction: 14%, hypophysitis: 6% and autoimmune diabetes: 0.6%). Combination immunotherapy was more likely to result in a single or multiple endocrinopathy compared to anti-PD-1 monotherapy (27% vs 9% and 7% vs 0% respectively,P < 0.01). Endocrinopathies occurred after a median of 8 weeks from treatment commencement (range: 12–225 days), with combination immunotherapy resulting in significantly earlier onset compared to ipilimumab (median: 30 vs 76 days,P = 0.046). The majority of endocrinopathies were identified in asymptomatic patients with hormonal screening. There were no baseline predictors for endocrinopathy. Conclusions: Combination immunotherapy has a greater risk of development of endocrinopathy compared to anti-PD-1 monotherapy. Regular biochemical profiling of patients, particularly within the first twelve weeks, results in early detection of endocrinopathy to minimise morbidity.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-17-0810

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 28

  1. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort., Presented at the 2016 Annual Meeting of the American Society of Clinical Oncology
  2. 2014, Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis, Clinical Neurology and Neurosurgery, 125, 125, 10.1016/j.clineuro.2014.06.011 · DOI
  3. 2015, Immune checkpoint blockade in cancer therapy, Journal of Clinical Oncology, 33, 1974, 10.1200/JCO.2014.59.4358 · DOI · Paper page
  4. 2010, Improved survival with Ipilimumab in patients with metastatic melanoma, New England Journal of Medicine, 363, 711, 10.1056/NEJMoa1003466 · DOI · Paper page
  5. 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, Journal of Clinical Oncology, 30, 2691, 10.1200/JCO.2012.41.6750 · DOI · Paper page
  6. 2016, Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review, Clinical Endocrinology, 85, 331, 10.1111/cen.13063 · DOI · Paper page
  7. 2010, The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications., Seminars in Oncology, 37, 499, 10.1053/j.seminoncol.2010.09.007 · DOI · Paper page
  8. 2015, Pembrolizumab versus Ipilimumab in advanced melanoma, New England Journal of Medicine, 372, 2521, 10.1056/NEJMoa1503093 · DOI · Paper page
  9. 2016, Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights, Pituitary, 19, 82, 10.1007/s11102-015-0671-4 · DOI · Paper page
  10. 2015, Nivolumab in previously untreated melanoma without BRAF mutation, New England Journal of Medicine, 372, 320, 10.1056/NEJMoa1412082 · DOI · Paper page
  11. 2017, Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature., Targeted Oncology, 12, 235, 10.1007/s11523-017-0480-y · DOI
  12. 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune check point antibodies, Annals of Oncology, 26, 2375, 10.1093/annonc/mdv383 · DOI · Paper page
  13. 2014, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocrine-Related Cancer, 21, 371, 10.1530/ERC-13-0499 · DOI · Paper page
  14. 2013, Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma, Cancer, 119, 1675, 10.1002/cncr.27969 · DOI · Paper page
  15. 2012, Hypophysitis induced by monoclonal antibodies to Cytotoxic T Lymphocyte Antigen 4: challenges from a new cause of a rare disease, Oncologist, 17, 525, 10.1634/theoncologist.2011-0404 · DOI
  16. 2015, Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy, Diabetes Care, 38, 55, 10.2337/dc14-2349 · DOI · Paper page
  17. 2015, Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma, New England Journal of Medicine, 372, 2006, 10.1056/NEJMoa1414428 · DOI · Paper page
  18. 2014, Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma, Journal of Clinical Endocrinology and Metabolism, 99, 4078, 10.1210/jc.2014-2306 · DOI · Paper page
  19. 2013, Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy, Experimental and Clinical Endocrinology and Diabetes, 121, 581, 10.1055/s-0033-1355337 · DOI
  20. 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Current Opinion in Immunology, 24, 207, 10.1016/j.coi.2011.12.009 · DOI · Paper page
  21. 2016, Low level autoantibodies can be frequently detected in the general Australian population, Pathology, 48, 483, 10.1016/j.pathol.2016.03.014 · DOI
  22. 2017, Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma., Journal of Clinical Oncology, 35, 785, 10.1200/JCO.2015.66.1389 · DOI · Paper page
  23. 2015, Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma, New England Journal of Medicine, 373, 23, 10.1056/NEJMoa1504030 · DOI · Paper page
  24. 2013, Endocrine side effects induced by immune checkpoint inhibitors, Journal of Clinical Endocrinology and Metabolism, 98, 1361, 10.1210/jc.2012-4075 · DOI · Paper page
  25. 2014, Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study, Cancer Research, 21, 749
  26. 2016, Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy, Cancer Treatment Reviews, 45, 7, 10.1016/j.ctrv.2016.02.003 · DOI · Paper page
  27. 2015, Long term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anto-CTLA-4 antibody in melanoma, European Journal of Endocrinology, 172, 195, 10.1530/EJE-14-0845 · DOI · Paper page
  28. 2012, Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review., European Journal of Endocrinology, 167, 1, 10.1530/EJE-12-0167 · DOI

Cited by

See all 142

Metadata

Authors
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H.
Affiliations
The University of Sydney (AU)
Corresponding author
Tsang, Venessa H
Venue
European Journal of Endocrinology
Published
2018-02
Volume
178
Issue
2
Pages
173-180
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2769908638
Cited by
142
References
30
Citations by year
2025: 9 · 2024: 12 · 2023: 17 · 2022: 19 · 2021: 23 · 2020: 25 · 2019: 22 · 2018: 15
FWCI
7.47
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
endocrine disorders, immune-related adverse events, immune checkpoint inhibitors, metastatic melanoma, ipilimumab, anti-PD-1 therapy, nivolumab, pembrolizumab, combination immunotherapy, thyroid dysfunction, hypophysitis, autoimmune diabetes
MeSH terms
Hypophysitis, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Australia, Autoimmune Diseases, Diabetes Mellitus, Drug Therapy, Combination, Endocrine System Diseases, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Prospective Studies, Thyroid Diseases, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. https://app.cochat.ai/papers/10.1530/eje-17-0810
The paper
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018). The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European Journal of Endocrinology. https://doi.org/10.1530/eje-17-0810

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.